This invention is directed to inhibitors of copper-containing amine oxidases (E.C. 1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-1), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.
这项发明涉及
铜含量胺氧化酶(E.C. 1.4.3.6)的
抑制剂,包括半胱
氨酸敏感胺氧化酶(S
SAO;也称为血管粘附蛋白-1,VAP-1),以及它们在炎症性疾病、糖尿病及其相关并发症、动脉粥样硬化、神经退行性疾病、肥胖症、高血压和癌症中的治疗用途。